



2018 CASL SINGLE TOPIC CONFERENCE **DECOMPENSATED CIRRHOSIS: FROM CLINIC TO TRANSPLANT**

FRIDAY OCTOBER 12TH

- 17:00** Welcome reception
- 19:00** Dinner
- 19:30** **Acute-on-chronic liver failure**
by Rajiv Jalan (University College London, UK)

SATURDAY OCTOBER 13TH

Session 1 – Hepatic Encephalopathy

Learning Objectives

At the end of this session, participants will/will be able to:

- Review the underlying pathophysiological mechanisms of hepatic encephalopathy
- Recognize the impact of hepatic encephalopathy on relevant clinical outcomes
- Understand the influence of the etiology of cirrhosis on cognitive decline
- Review current management strategies for hepatic encephalopathy

- 8:00** **Gut-liver-brain axis**
by Christopher Rose (CRCHUM, Montréal, Québec)
- 8:30** **Cognitive decline pre-cirrhosis**
by Mark Swain (Calgary University, Calgary, Alberta)
- 9:00** **Diagnosis and management of hepatic encephalopathy**
by Jasmohan Bajaj (Virginia Commonwealth University, USA)

-
- 9:30** Coffee break
-

Session 2 – Bleeding and Coagulopathy in Cirrhosis

Learning Objectives

At the end of this session, participants will/will be able to:

- Discuss endoscopic and non-invasive variceal screening methods in decompensated cirrhosis
- Review the management of variceal bleeding
- Understand abnormalities in coagulation/hemostasis in decompensated cirrhosis
- Evaluate the role of anticoagulation in cirrhotic patients with thromboembolic complications

10:00	Primary variceal screening: Is endoscopy required? <i>by Juan Abraldes (University of Alberta, Edmonton, Alberta)</i>
10:30	Management of variceal bleeding <i>by Julien Bissonnette (CHUM, Montréal, Québec)</i>
11:00	When do you treat portal vein thrombosis <i>by Vladimir Marquez (Vancouver General Hospital, Vancouver, British-Columbia)</i>
11:30	Coagulopathy in cirrhosis <i>by Todd Stravitz (Virginia Commonwealth University, USA)</i>

12:00 **Lunch**

Session 3 – Muscle and Nutrition in Cirrhosis

Learning Objectives

At the end of this session, participants will/will be able to:

- Understand the impact of sarcopenia in cirrhosis
- Review current concepts about nutrition in cirrhosis/ACLF
- Describe the role of palliative care in ACLF/cirrhotic patients declined for liver transplant
- Recognize the impact of HE on driving

13:30	Impact of sarcopenia <i>by Aldo Montano-Loza (University of Alberta, Edmonton, Alberta)</i>
14:00	Nutrition and cirrhosis <i>by Manuela Merli (Sapienza University of Rome, Italy)</i>
14:30	Breakout session A 1. Hepatic encephalopathy and driving <i>by Phil Wong (McGill University, Montréal, Québec)</i> 2. Palliative care in the cirrhotic patient <i>by Puneeta Tandon (University of Alberta, Edmonton, Alberta)</i>

15:30

Coffee break

Session 4 – Critical Care and Liver Transplant in the ACLF Patient

Learning Objectives

At the end of this session, participants will/will be able to:

- Discuss critical care management of the ACLF patient with multiorgan failure
- Review the evidence for artificial/bioartificial liver support in ACLF
- Review perioperative challenges in the ACLF patient undergoing liver transplant
- Understand the challenges of determining futility in ACLF patient undergoing liver transplantation

16:00

Critical care management of the ACLF patient in the ICU

by Julia Wendon (King's College Hospital, UK)

16:30

Artificial liver support

by Scott Nyberg (Mayo Clinic, USA)

17:00

Perioperative management during liver transplantation

by François Carrier (CHUM, Montréal, Québec)

17:30

Liver transplant: challenges in predicting futility

by Dean Karvellas (University of Alberta, Edmonton, Alberta)

19:00

Reception

19:30

Dinner

20:00

Towards a unified definition and future research opportunities

by Patrick Kamath (Mayo Clinic, USA)

Session 5 – Complications and Treatments

Learning Objectives

At the end of this session, participants will/will be able to

- Review the epidemiology and therapies of acute kidney injury (AKI) in cirrhosis
- Recognize the impact of sepsis in cirrhosis and the rational use of antibiotics
- Understand the role and challenges of Hepatitis C Virus (HCV) eradication in decompensated cirrhosis
- Discuss evolving role of liver transplant in patients with alcohol-related liver disease

8:00

Breakout session B

1. Sepsis and antimicrobials: A clinical challenge

by Jody Olson (University of Kansas Medical Center)

2. Controversies in liver transplantation: Alcoholic hepatitis

by Michael Lucey (University of Wisconsin, USA)

9:00

Hepatorenal syndrome/AKI in cirrhosis

by Florence Wong (University Health Network, Toronto, Canada)

9:30

Benefit of hepatitis C treatment in decompensated cirrhosis

by Jordan Feld (University Health Network, Toronto, Canada)

10:00

Coffee break

Session 6 – Interactive Session

10:30

Case reports with treatment/management strategies – “live” survey

12:00

Meeting is over.

13:30

Mini-putt tournament